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For clinical cases, few differences have been observed 
between ACE and TG 43 in Gynecologic cases (up to 2.75% 
differences on the CTV and up to 1%,2% and 6% for D2cc of 
sigmoid, rectum and bladder respectively. For Penis cases 
large differences in glans volume covered by the 200% 
isodose up to 70% have been observed, and up to 10% for the 
100% isodose volume in lips cases. 
 
Conclusion: We have demonstrated that the use of an 
advance algorithm for Brachytherapy dose calculation is 
clinically and physically feasible. It shows good agreements 
with measured data. The use of such algorithms opens 
questions regarding the prescription and tolerances allowed 
in clinical use. 
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Purpose or Objective: Accurately locating the source dwell 
positions within HDR brachytherapy applicators is essential to 
ensure accurate reconstruction of the radioactive source path 
within the applicator for commissioning. Traditional 
approaches using radiochromic film are inefficient and 
limited to one or few dwell positions per film. The aim of this 
study was to develop a filmless procedure using a flat panel 
detector (FPD) source tracking system to accurately 
determine every dwell position and to correlate these with 
radio-opaque markers. 
 
Material and Methods: The method was applied to two 
gynaecological HDR treatment applicators, incorporating 
interuterine tube/ovoids and an interuterine tube/ring 
combination. The disassembled applicators were fixed to the 
FPD. Auto-radiographs were captured by the FPD while the 
HDR source was dwelled at each available position. The 
location of the source was determined from these images. 
Using an external x-ray source, a radiograph was also 
captured, acquiring a combined exposure image. A 
subtraction method was then used to visualise the physical 
source in the applicator channel. Radiographs were also 
acquired with radio-opaque markers installed. Results of this 
new method were compared to traditional radiochromic film 
methods for distal dwell positions to compare commissioning 
approaches. 
 
Results: The double-exposure image subtraction technique 
provided a method for visualising the active source and 
accurately determining its true location for all available 
dwell positions in each applicator channel (see Figure 1). 
Furthermore, determining the source dwell positions from 
the radiograph alone agreed with this projection-subtraction 
technique to < 1.0 mm for 34 out of the 35 available dwells 
of the ring channel (as an example). One position differed by 
1.4 mm having been influenced by a high contrast feature in 
the radiograph. Distance to coincidence between the actual 
source positions and three positions identified by radio-
opaque markers in the ring (dwells 1, 16, and 30) were 





Figure 1: (a) Autoradiograph (source radiation) captured by 
the FPD. (b) Simultaneous external x-ray exposure and source 
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autoradiograph. (c) The subtracted image clearly showing the 
physical position of the source in the applicator and path of 
the drive cable through the applicator lumen. 
 
Conclusion: We have demonstrated a filmless approach to 
determining actual source positions corresponding to each 
dwell position in each channel of two gynaecological HDR 
brachytherapy applicators. Accuracy is generally sub-
millimetre and can also be used to quantify the accuracy of 
using marker-wire defined positions for reconstructing 
applicators in planning. The flat panel detector method is 
efficient and provides additional information not possible 
with radiochromic film. 
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Purpose or Objective: Salvage Iodine-125 brachytherapy (I-
125-BT) constitutes a curative treatment approach for 
patients with organ-confined recurrent prostate cancer after 
primary radiotherapy. Currently, focal salvage (FS) instead of 
whole-gland or total salvage (TS) is being investigated, to 
reduce severe toxicity associated with cumulative radiation 
dose. Differences in urethral and bladder dosimetry and 
constraints to reduce late (>90 days) genitourinary (GU) 
toxicity are presented here. 
 
Material and Methods: Dosimetry on intraoperative 
ultrasound (US) of 20 FS and 28 TS patients was compared. 
The prostate, bladder, urethra (figure 1) and 
bulbomembranous (BM) urethra were delineated. Toxicity 
was assessed using the CTCAE version 4.0. Dose constraints to 
reduce toxicity in TS patients were evaluated with receiver 




Figure. 1. Urethral (= yellow) D10 difference for TS (A) 
compared FS (B). The urethral D10 in A was 270 Gy versus 100 
Gy in B. 
 
Results: FS I-125 BT significantly reduces bladder and 
urethral dose compared to TS. Grade 3 GU toxicity occurred 
once in the FS group. For TS patients late severe (≥grade 3) 
GU toxicity was frequent (38% in the total 61 patients and 
56% in the 27 analyzed patients). TS patients with ≥grade 3 
GU toxicity showed higher bladder D2cc than TS patients 
without toxicity (median 43 Gy) (p = 0.02). The urethral V100 
was significantly higher in TS patients with several toxicity 
profiles:≥grade 3 urethral strictures,≥grade 2 urinary 
retention and multiple ≥grade 2 GU toxicity events. Dose to 
the BM urethra did not show a relation with stricture 
formation. ROC-analysis indicated a bladder D2cc <70 Gy to 
prevent ≥grade 3 GU toxicity (AUC 0.76, 95%CI: 0.56–0.96, p = 
0.02). A urethral V100 <0.40 cc (AUC from 0.73–0.91, p = 
0.003–0.05) could prevent other late GU toxicity. 
 
Conclusion: FS I-125 BT reduces urethral and bladder dose 
significantly compared to TS. With TS, there is an increased 
risk of cumulative dose and severe GU toxicity. Based on 
these findings, bladder D2cc should be below 70 Gy and 
urethral V100 below 0.40 cc. 
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Purpose or Objective: To report 5 and 8-year clinical 
outcomes, early and late complications in 226 patients with 
prostate cancer treated with high-dose-rate brachytherapy 
(HDR-BT) in combination with external-beam radiotherapy 
(EBRT). 
 
Material and Methods: Between 2004 and 2010, 226 patients 
underwent HDR-BT in combination with EBRT as a treatment 
for their low, intermediate or high risk prostate cancer. The 
HDR-BT procedure was performed using ultrasound-based 
transperineal implantation. The total HDR-BT dose was 16 - 
18Gy in 2. The EBRT technique used by treatment was 3D-
CRT (70.3%) or IGRT/IMRT (29.7%) with daily correction of set 
up errors. Total dose of EBRT for low risk patients was 45Gy 
in 25 fractions of 1.8Gy within 5 weeks. For intermediate and 
high-risk patients the dose was 50.4Gy in 28 of 1.8Gy within 5 
weeks. Patients were stratified by risk factors in to risk 
groups – 67 (29.5%) low, 87 (38.5%) intermediate and 72 
(32.0%) high risk patients. Neoadjuvant hormonal therapy was 
applied in patient of intermediate or high risk of recurrence. 
High risk patients recieved adjuvant hormonal therapy.  
 
Results: 5-year results after a mean follow-up of 70 months 
of the 226 patients the freedom from biochemical failure was 
92.5%. 17 patients (7.5%) showed prostate specific antigen 
progression according to the Phoenix definition. In 9 patients 
clinical progression (bone or lymph node metastases) was 
documented. 8-year results after a mean follow up of 96 
months of the 130 patients the freedom from biochemical 
failure was 82%. 23 patients (18.0%) showed prostate specific 
antigen progression. In 11 patients clinical progression was 
documented. Cancer specific survival during 5-year and 8-
year follow up was 99.1% and 96.8% respectively. Toxicity 
was scored using the EORTC/RTOG score system. During 
follow up we haven´t observed any consequential toxicity or 
relationship between acute and late toxicity respectively. 
Higher incidence of GU and GIT toxicity was observed in 
patients treated by 3D-CRT technique. Acute and late 
gastrointestinal toxicity (GIT) was very low. Toxicity grade 2 
was observed in 1.3% No grade 3 or 4 GIT toxicity was 
observed. Acute GU toxicity in most cases was grade 1 
(40.2%) or grade 2 (10.6%). Late GU toxicity was also in most 
cases grade 1 (32.7%) or grade 2 (10.1%). Grade 3 toxicity was 
observed only in 2.2%. Grade 4 toxicity didn´t occurred. We 
have detected a trend that higher grade late GU toxicity was 
observed after longer period of treatment than lower grade. 
Mean time of occurrence for grade 3 and 2 was 64 and 23 
months respectively, compared to mean time 12 months for 
grade 1. 
 
Conclusion: Combination of external beam radiotherapy with 
high-dose-rate interstitial brachytherapy boost is safety and 
effective option in treatment localized prostate cancer. Our 
results show a low incidence of acute and late complications 
with favorable oncologic outcome after 5 and 8 year follow 
up.  
 
 
 
 
